Table 1 Patient characteristics in Study 1
Patient characteristics | La deposition (+), n = 23 | La deposition (−), n = 19 | Odds ratio (95% CI) | p value |
|---|---|---|---|---|
Male sex, n (%) | 14 (60.9%) | 13 (68.4%) | 1.39 (0.39–5.01) | 0.258 |
Age, median (range) | 72 (47–82) | 68 (45–83) | – | 0.909 |
Gastric mucosal atrophy (mild, medium, severe)*, n (%) | 5 (21.7%), 7 (30.4%), 11 (47.8%) | 7 (36.8%), 3 (15.8%), 9 (47.4%) | – | 0.413 |
Primary diseases of dialysis (diabetes, hypertension, nephritis), n (%) | 8 (34.8%), 3 (13.4%), 12 (52.2%) | 10 (52.6%), 2 (10.5%), 7 (36.8%) | – | 0.504 |
Years since start of dialysis, median (range) | 7.32 (0.70–26.4) | 5.83 (1.57–14.2) | – | 0.092 |
Months of oral use of LaC, median (range) | 34 (4–70) | 28 (10–72) | – | 0.206 |
Daily dose of LaC, mg, median (range) | 1000 (500–1500) | 750 (250–1500) | – | 0.104 |
Total dose of LaC, g, median (range) | 990 (180–3150) | 480 (225–1328) | – | 0.013 |
Ca, mg/dL, median (range) (number of missing data: 4) | 8.9 (8–10.2) | 8.4 (7.2–9.9) | – | 0.084 |
IP, mg/dL, median (range) (number of missing data: 7) | 5.5 (3.5–8.1) | 5.3 (3.1–8.3) | – | 0.586 |
TP, g/dL, median (range) (number of missing data: 8) | 6.4 (4.8–7.9) | 6.35 (4.3–7.3) | – | 0.479 |
Albumin, g/dL, median (range) (number of missing data: 7) | 3.5 (2.7–4.0) | 3.6 (2.4–4.0) | – | 0.752 |
Total cholesterol, mg/dL, median (range) (number of missing data: 10) | 166 (103–203) | 151 (88–240) | – | 0.454 |
HDL–cholesterol, mg/dL, median (range) (number of missing data: 13) | 47 (24–67) | 47 (18–97) | – | 0.790 |
Triglyceride, mg/dL, median (range) (number of missing data: 9) | 103 (50–336) | 94.5 (35–198) | – | 0.649 |
WBC, /µL, median (range) (number of missing data: 6) | 5460 (3370–8300) | 6535 (2650–12,470) | – | 0.133 |
Hemoglobin, g/dL, median (range) (number of missing data: 5) | 10.5 (7.3–12.5) | 10.55 (7.3–12.8) | – | 0.976 |
NSAIDs (including low–dose aspirin), n (%) | 10 (43.5%) | 10 (52.6%) | 0.69 (0.20–2.35) | 0.554 |
PPIs, n (%) | 17 (73.9%) | 17 (89.5%) | 0.33 (0.06–1.89) | 0.201 |
PPIs + H2RAs, n (%) | 21 (91.3%) | 17 (89.5%) | 1.24 (0.16–9.71) | 0.841 |
Gastric mucoprotective drugs, n (%) | 9 (39.1%) | 4 (21.1%) | 2.41 (0.60–9.63) | 0.207 |